Oncothyreon builds targeted portfolio with Alpine buy
This article was originally published in Scrip
Executive Summary
Oncothyreon purchased privately-held Alpine Biosciences in an all-stock transaction valued at $27m to acquire in-house drug discovery capabilities and develop less toxic, targeted cancer therapies.